,15, 16, 17 Our study shows that both Class II and III MAP2K1 mutations can serve as primary drivers in nevi, melanocytomas, and melanomas in the absence of co-drivers in the MAPK pathway. The gene discussed is MAP2K1; the disease is melanoma.